Compare Moderna, Inc. (MRNA) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Williams Companies Inc — how do they compare? Moderna, Inc. trades at $60.51 (market cap $24.18B), while Williams Companies Inc trades at $73.75 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 3.7× Moderna, Inc.'s market cap, and Williams Companies Inc pays a 2.9% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WMB | |
|---|---|---|
Market Cap | $24.18B | $88.45B |
Sector | Health | Energy |
52-Week High | $81.80 | $79.40 |
52-Week Low | $22.36 | $56.51 |
Enterprise Value | $20.33B | $119.07B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Williams Companies (WMB) trades at $73.60, up 2.44% with a bullish technical signal despite mixed earnings history. The company reported strong Q1 2026 results but missed Q2 estimates, while raising full-year EBITDA guidance to $8.4 billion. Analyst consensus remains strongly bullish with a $87.14 price target, supported by the recent $5.5 billion Momentum Midstream acquisition that enhances Gulf Coast exposure and supports 11% annual growth targets through 2030.
WMB presents a compelling investment case with strong profitability metrics (25.18% net margin, 24.02% ROE) and dividend stability ($2.10 annualized). Key risks include execution challenges from the Momentum integration, debt levels at 52.07% of assets, and potential volatility from energy market fluctuations. The stock offers 18% upside to consensus target with institutional support despite recent position reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
